-transparent.png){kind=logo}
A 54-yr-old man with lymphoma and serological evidence of prior hepatitis B virus (HBV) infection, with detectable anti-HBc and anti-HBs, was treated with intensive chemotherapy. He had reactivation of HBV infection with acute hepatitis B manifest by detectable HBsAg and elevated aminotransferase levels >1000 IU/L. He was treated with lamivudine 150 mg daily and had prompt resolution of acute hepatitis B with return of elevated aminotransferases to normal, and initial loss of HBeAg with later loss of HBsAg. Lamivudine was continued during the course of further chemotherapy as prophylaxis against repeat HBV reactivation. Lamivudine is a nucleoside analogue that is a potent inhibitor of HBV reverse transcriptase and HBV replication. Lamivudine therapy should be considered for the treatment of HBV reactivation and might play a future role as preemptive therapy of HBV reactivation in patients with prior hepatitis B or chronic hepatitis B with inactive viral replication.
A Ahmed, and
E B Keeffe
October 2004,
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
A Ahmed, and
E B Keeffe
October 2006,
Alimentary pharmacology & therapeutics,
A Ahmed, and
E B Keeffe
May 2001,
The American journal of gastroenterology,
A Ahmed, and
E B Keeffe
May 2003,
The American journal of gastroenterology,
A Ahmed, and
E B Keeffe
February 2011,
Gan to kagaku ryoho. Cancer & chemotherapy,
A Ahmed, and
E B Keeffe
March 2004,
Journal of viral hepatitis,
A Ahmed, and
E B Keeffe
July 2002,
Blood,
A Ahmed, and
E B Keeffe
November 2007,
Clinics in liver disease,
A Ahmed, and
E B Keeffe
November 1999,
Journal of medical virology,
A Ahmed, and
E B Keeffe
January 2006,
Gastroenterologia y hepatologia,
